Member Info for Soupdragon78

Quite possible, although we know Keegan is part time and has been mostly spending time getting his advanced biker license.

Whilst there will (hopefully) have been some negotiations, there surely plenty of other opportunities in the same vain as the Vista deal that Blackwell should be developing.

The good thing about Dan was that he was always out networking and getting the company name out there. Doesn't feel the same at present.

Chab, they've not begun in the UK as not registered with MHRA.

Its frustrating the silence from the company, compared to when DG was involved. At least he would communicate.

As I've said before, what exactly does Blackwell do day to day?

Jo and Alex, I can understand as they are lab based. But Blackwell and Keegan?

Probably best stick with ‘deal soon’ like we’ve had for the past four months.

Wonder if Mazik’s ‘news this week’ is going to land.

Especially as they have previously worked with Vectura and completed studies in inhaler use of cocrystal back in 2015

https://www.nuformix.com/news/nuformix-and-vectura-complete-1m-innovate-uk-research-grant/

I see other companies have now moved on to clinical trials for their spray administered Covid treatment. Hope NfX have moved past just reading some research papers.

It was below mid price so automatically gets put in the sell column by LSE.

Nothing untoward. Just the way this website works.

Whether it has side effects or not is the point of the next clinical trials.

Just looking for possible comparison deals.

Back in 2014 Shire Pharmaceutical snapped up Aussie company Fibrotech for $75m up front and $600m milestone payments.

Especially interesting as their lead product FT011 was for fibrosis and based on using Tranilast.

Shire was subsequently bought by Asia’s biggest Pharma company Takeda. (Which then dropped Ft011)

https://www.ausbiotech.org/about-us/30-success-stories/12-fibrotech

It’s an interesting conundrum Mars, I don’t know the geographical make up of the IPF market, so difficult to see how the split might affect. Who knows how big the Japan/Asia market is?
At the end of the day, a percentage of a slightly smaller big number is still a big number.

Mars, devils advocate point of view, if those figures are global, what’s the value given tranilast is not FDA approved? Limiting its markets.

No worries. It’s an interesting change of tack from DG, moving into the AI side with Qur8.
With NfX he was categorically anti-AI and distanced the company from it.

“ I find AI still quite untangible - and I say this after experiences applying AI to our discovery and development: it's a black box from which we’re yet to see delivery of something a human couldn’t do.”

“ For example,” says Jo, “with NX002, I was looking for a completely different indication, if it was an algorithm it wouldn’t have gone off piste in the way that I did.”

https://www.cambridgeindependent.co.uk/news/nuformix-ai-cant-take-you-where-we-go-9066463/

Yuyu’s, is that the deepmind that Google bought up a few years ago?
What do you see as the relevance?

FX, you are right re. The trade deal with japan. It is useful because without it the uk would have lost mutual recognition at the end of the year. So they needed to desperately do something to retain the status quo. It also will increase gdp by 0.07% over the next 15 years which a positive given the governments own predictions of a loss of 7%.
So with the worlds 3rd biggest economy now signed up. Shouldn’t take much to fill the remaining.

Must be the ‘error’ we are living in, to quote a great Freudian slip.

Better to be woke than gullible.

Mars, the UK already had an MRA On Pharma products And medicine with Japan in place since 2004 as an EU member. The announcement yesterday was an agreement to continue.

You weren't the Mayor were you?

Don’t be silly!

Oooh, it’s exciting today today isn’t it, a bit of watch and learn for us all. The telegram group have copy pasted Chabs post of the Times article.

Close....Ask Alan Chorlton

Jay, here's the Times article.

https://www.thetimes.co.uk/article/rolls-royce-s-engine-faults-mean-it-may-have-to-refuel-3d9lrphfp